12 profili klinicznych pacjentów, u których warto rozważyć zastosowanie kandesartanu Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2023
Słowa kluczowe:
kandesartan, nadciśnienie tętnicze, ryzyko sercowo-naczyniowe
##plugins.themes.bootstrap3.article.main##
Abstrakt
Zgodnie z aktualnymi polskimi i europejskimi wytycznymi antagoniści receptora AT1 dla angiotensyny II należą do głównych grup leków stosowanych w terapii nadciśnienia tętniczego. Wiele badań wykazało, że sartany zmniejszają ryzyko wystąpienia powikłań nadciśnienia tętniczego, wywierają korzystny wpływ na profil metaboliczny, zmiany naczyniowe, funkcję nerek, a dodatkowo są najlepiej tolerowane spośród wszystkich preparatów hipotensyjnych. W artykule przedstawiono przykłady zastosowania kandesartanu w terapii nadciśnienia tętniczego, zwracając szczególną uwagę na jego skuteczność hipotensyjną, bezpieczeństwo stosowania u pacjentów w wieku podeszłym, korzystny wpływ na niewydolność serca, bóle migrenowe głowy czy przerost lewej komory.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Barylski , M. (2023). 12 profili klinicznych pacjentów, u których warto rozważyć zastosowanie kandesartanu . Medycyna Faktów , 16(4(61), 320-327. https://doi.org/10.24292/01.MF.0423.05
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Jędrusik P. Kandesartan i jego preparaty złożone u pacjentów z nadciśnieniem tętniczym i chorobami układu krążenia. Lek w Polsce. 2015; 25(4): 14-31.
2. Julius S, Nesbitt SD, Egan BM et al. Feasibility of treating prehypertension with an angiotensin receptor blocker. N Engl J Med. 2006; 354: 1685-97.
3. Easthope SE, Jarvis B. Candesartan cilexetil: an update of its use in essential hypertension. Drugs. 2002; 62: 1253-87.
4. Khawaja Z, Wilcox CS. An overview of candesartan in clinical practice. Expert Rev Cardiovasc Ther. 2011; 9: 975-82.
5. Ross A, Papademetriou V. Candesartan cilexetil in cardiovascular disease. Exp Rev Cardiovasc Ther. 2004; 2: 829-35.
6. McInnes GT, O’Kane KP, Jonker J et al. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population. J Hum Hypertens. 1997; 11(suppl 2): S75-S80.
7. Himmelmann A, Keinanen-Kiukaanniemi S, Wester A et al. The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension. Blood Press. 2001; 10: 43-51.
8. Bakris G, Gradman A, Reif M et al. Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. J Clin Hypertens. 2001; 3: 16-21.
9. Vidt DG, White WB, Ridley E et al. A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II. J Hum Hypertens. 2001; 15: 475-80.
10. Zheng Z, Shi H, Jia J et al. A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension. J Renin Angiotensin Aldosterone Syst. 2011; 12: 365-74.
11. Ozaki N, Nomura Y, Sobajima H et al. Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus. Eur J Intern Med. 2010; 21: 236-9.
12. Kloner RA, Weinberger M, Poole JL et al. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Am J Cardiol. 2001; 87: 727-31.
13. Eguchi K. Comparison of candesartan with lisinopril on ambulatory blood pressure and morning surge in patients with systemic hypertension. Am J Cardiol. 2003; 92: 621-4.
14. Melian EB, Jarvis B. Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension. Drugs. 2002; 62: 787-816.
15. Edes I. Combination therapy with candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg provides the full additive antihypertensive effect of the components: a randomized, double-blind, parallel-group study in primary care. Clin Drug Invest. 2009; 29: 293-304.
16. Bönner G. Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy. Blood Press. 2008; 17(suppl 2): 22-30.
17. Koenig W. Comparison of the efficacy and tolerability of combination tablets containing candesartan cilexetil and hydrochlorothiazide or losartan and hydrochlorothiazide in patients with moderate to severe hypertension: results of the CARLOS-Study. Clin Drug Invest. 2000; 19: 239-46.
18. Bönner G, Fuchs W. Fixed combination of candesartan with hydrochlorothiazide in patients with severe primary hypertension. Curr Med Res Opin. 2004; 20: 597-602.
19. Tronvik E, Stovner LJ, Helde G et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003; 289: 65-9.
20. Szczepaniak-Chicheł L. Kandesartan. In: Szczepaniak-Chicheł L, Tykarski A (ed). Biblioteka czasopisma Nadciśnienie Tętnicze. Via Medica, Gdańsk 2009: 1-56.
21. Ogihara T, Nakao K, Fukui T et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks. Candesartan Antihypertensive Survival Evaluation in Japan trial. Hypertension. 2008; 51: 393-8.
22. Cuspidi C, Muiesan ML, Valagussa L et al.; CATCH investigators. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens. 2002; 20: 2293-300.
23. Barrios V, Escobar C, Calderón A et al. Regression of left ventricular hypertrophy by a candesartan-based regimen in clinical practice. The VIPE study. J Renin Angiotensin Aldosterone Syst. 2006; 7: 236-42.
24. Wożakowska-Kapłon B, Gorczyca-Michta I. Terapia nadciśnienia tętniczego – kiedy warto wybrać kandesartan? Choroby Serca i Naczyń. 2013; 10(6): 301-8.
25. Papademetriou V, Farsang C, Elmfeldt D et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol. 2004; 44: 1175-80.
26. Zanchetti A, Elmfeldt D. Findings and implications of the Study on Cognition and Prognosis in the Elderly (SCOPE) – a review. Blood Press. 2006; 15: 71-9.
27. Hajjar I, Hart M, Chen Y-L et al. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial. Arch Intern Med. 2012; 172: 442-4.
28. Lindholm LH, Persson M, Alaupovic P et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens. 2003; 21: 1563-74.
29. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Programme. Lancet. 2003; 362: 759-66.
30. Grassi G, Seravalle G, Dell’Oro R et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity and sympathetic drive in obese hypertensive individuals: results of the CROSS Study. J Hypertens. 2003; 21: 1761-9.
31. Bilous R, Chaturvedi N, Sjolie AK et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med. 2009; 151: 11-20.
32. Tamura Y, Kosuga M, Yamashita M et al. Renoprotective effects of angiotensin II receptor blocker, candesartan cilexetil, in patients with stage 4-5 chronic kidney disease. Clin Exp Nephrol. 2008; 12: 256-63.
33. Ducharme A, Swedberg K, Pfeffer MA et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Am Heart J. 2006; 151: 86-92.
34. Kasanuki H, Hagiwara N, Hosoda S et al. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J. 2009; 30: 1203-12.
35. Schrader J, Luders S, Kuschewski A et al. The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke. 2003; 34: 1699-703.
36. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left ventricular systolic function: the CHARM-Preserved trial. Lancet. 2003; 362: 777-81.
37. McMurray JJ, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function treated with an ACE inhibitor: the CHARM-Added trial. Lancet. 2003; 362: 767-71.
38. Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function and intolerant to ACE inhibitors: the CHARM-Alternative Trial. Lancet. 2003; 362: 772-6.
39. Riegger GAJ, Bouzo H, Petr P et al. Improvement in Exercise Tolerance and Symptoms of Congestive Heart Failure During Treatment with Candesartan Cilexetil (STRETCH). Circulation. 1999; 100: 2224-30.
40. Tykarski A, Filipiak KJ, Januszewicz A et al. Zasady postępowania w nadciśnieniu tętniczym – 2019 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze w Praktyce. 2019; 5(1): 1-84.
2. Julius S, Nesbitt SD, Egan BM et al. Feasibility of treating prehypertension with an angiotensin receptor blocker. N Engl J Med. 2006; 354: 1685-97.
3. Easthope SE, Jarvis B. Candesartan cilexetil: an update of its use in essential hypertension. Drugs. 2002; 62: 1253-87.
4. Khawaja Z, Wilcox CS. An overview of candesartan in clinical practice. Expert Rev Cardiovasc Ther. 2011; 9: 975-82.
5. Ross A, Papademetriou V. Candesartan cilexetil in cardiovascular disease. Exp Rev Cardiovasc Ther. 2004; 2: 829-35.
6. McInnes GT, O’Kane KP, Jonker J et al. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population. J Hum Hypertens. 1997; 11(suppl 2): S75-S80.
7. Himmelmann A, Keinanen-Kiukaanniemi S, Wester A et al. The effect duration of candesartan cilexetil once daily, in comparison with enalapril once daily, in patients with mild to moderate hypertension. Blood Press. 2001; 10: 43-51.
8. Bakris G, Gradman A, Reif M et al. Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study. J Clin Hypertens. 2001; 3: 16-21.
9. Vidt DG, White WB, Ridley E et al. A forced titration study of antihypertensive efficacy of candesartan cilexetil in comparison to losartan: CLAIM Study II. J Hum Hypertens. 2001; 15: 475-80.
10. Zheng Z, Shi H, Jia J et al. A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension. J Renin Angiotensin Aldosterone Syst. 2011; 12: 365-74.
11. Ozaki N, Nomura Y, Sobajima H et al. Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus. Eur J Intern Med. 2010; 21: 236-9.
12. Kloner RA, Weinberger M, Poole JL et al. Comparative effects of candesartan cilexetil and amlodipine in patients with mild systemic hypertension. Am J Cardiol. 2001; 87: 727-31.
13. Eguchi K. Comparison of candesartan with lisinopril on ambulatory blood pressure and morning surge in patients with systemic hypertension. Am J Cardiol. 2003; 92: 621-4.
14. Melian EB, Jarvis B. Candesartan cilexetil plus hydrochlorothiazide combination: a review of its use in hypertension. Drugs. 2002; 62: 787-816.
15. Edes I. Combination therapy with candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg provides the full additive antihypertensive effect of the components: a randomized, double-blind, parallel-group study in primary care. Clin Drug Invest. 2009; 29: 293-304.
16. Bönner G. Antihypertensive efficacy and tolerability of candesartan-hydrochlorothiazide 32/12.5 mg and 32/25 mg in patients not optimally controlled with candesartan monotherapy. Blood Press. 2008; 17(suppl 2): 22-30.
17. Koenig W. Comparison of the efficacy and tolerability of combination tablets containing candesartan cilexetil and hydrochlorothiazide or losartan and hydrochlorothiazide in patients with moderate to severe hypertension: results of the CARLOS-Study. Clin Drug Invest. 2000; 19: 239-46.
18. Bönner G, Fuchs W. Fixed combination of candesartan with hydrochlorothiazide in patients with severe primary hypertension. Curr Med Res Opin. 2004; 20: 597-602.
19. Tronvik E, Stovner LJ, Helde G et al. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003; 289: 65-9.
20. Szczepaniak-Chicheł L. Kandesartan. In: Szczepaniak-Chicheł L, Tykarski A (ed). Biblioteka czasopisma Nadciśnienie Tętnicze. Via Medica, Gdańsk 2009: 1-56.
21. Ogihara T, Nakao K, Fukui T et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks. Candesartan Antihypertensive Survival Evaluation in Japan trial. Hypertension. 2008; 51: 393-8.
22. Cuspidi C, Muiesan ML, Valagussa L et al.; CATCH investigators. Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) study. J Hypertens. 2002; 20: 2293-300.
23. Barrios V, Escobar C, Calderón A et al. Regression of left ventricular hypertrophy by a candesartan-based regimen in clinical practice. The VIPE study. J Renin Angiotensin Aldosterone Syst. 2006; 7: 236-42.
24. Wożakowska-Kapłon B, Gorczyca-Michta I. Terapia nadciśnienia tętniczego – kiedy warto wybrać kandesartan? Choroby Serca i Naczyń. 2013; 10(6): 301-8.
25. Papademetriou V, Farsang C, Elmfeldt D et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol. 2004; 44: 1175-80.
26. Zanchetti A, Elmfeldt D. Findings and implications of the Study on Cognition and Prognosis in the Elderly (SCOPE) – a review. Blood Press. 2006; 15: 71-9.
27. Hajjar I, Hart M, Chen Y-L et al. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial. Arch Intern Med. 2012; 172: 442-4.
28. Lindholm LH, Persson M, Alaupovic P et al. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). J Hypertens. 2003; 21: 1563-74.
29. Pfeffer MA, Swedberg K, Granger CB et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Programme. Lancet. 2003; 362: 759-66.
30. Grassi G, Seravalle G, Dell’Oro R et al. Comparative effects of candesartan and hydrochlorothiazide on blood pressure, insulin sensitivity and sympathetic drive in obese hypertensive individuals: results of the CROSS Study. J Hypertens. 2003; 21: 1761-9.
31. Bilous R, Chaturvedi N, Sjolie AK et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med. 2009; 151: 11-20.
32. Tamura Y, Kosuga M, Yamashita M et al. Renoprotective effects of angiotensin II receptor blocker, candesartan cilexetil, in patients with stage 4-5 chronic kidney disease. Clin Exp Nephrol. 2008; 12: 256-63.
33. Ducharme A, Swedberg K, Pfeffer MA et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. Am Heart J. 2006; 151: 86-92.
34. Kasanuki H, Hagiwara N, Hosoda S et al. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J. 2009; 30: 1203-12.
35. Schrader J, Luders S, Kuschewski A et al. The ACCESS study: evaluation of acute candesartan cilexetil therapy in stroke survivors. Stroke. 2003; 34: 1699-703.
36. Yusuf S, Pfeffer MA, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and preserved left ventricular systolic function: the CHARM-Preserved trial. Lancet. 2003; 362: 777-81.
37. McMurray JJ, Ostergren J, Swedberg K et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function treated with an ACE inhibitor: the CHARM-Added trial. Lancet. 2003; 362: 767-71.
38. Granger CB, McMurray JJ, Yusuf S et al. Effects of candesartan in patients with chronic heart failure and reduced left ventricular systolic function and intolerant to ACE inhibitors: the CHARM-Alternative Trial. Lancet. 2003; 362: 772-6.
39. Riegger GAJ, Bouzo H, Petr P et al. Improvement in Exercise Tolerance and Symptoms of Congestive Heart Failure During Treatment with Candesartan Cilexetil (STRETCH). Circulation. 1999; 100: 2224-30.
40. Tykarski A, Filipiak KJ, Januszewicz A et al. Zasady postępowania w nadciśnieniu tętniczym – 2019 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze w Praktyce. 2019; 5(1): 1-84.